OUR SCIENCE
Prolanta™

Phase I clinical trials, anticipated to begin in Q4 2010, will be used to assess the safety (pharmacovigilance), tolerability, pharmacokinetics and
pharmacodynamics of Prolanta. Approximately 45 patients will be evaluated in the first clinical trial of Prolanta in metastatic breast cancer patients.

Currently, Oncolix is working with researchers at Clemson University in Greenville, SC, and M.D. Anderson Cancer Center in Houston, TX to conduct preclinical studies to evaluate the effect of Prolanta on cancer stem cells and ovarian cancer and to test Prolanta in combination with other anticancer agents used to treat breast and ovarian cancer. The results of these preclinical combination studies will be helpful in the planning of Phase II clinical trials.

As treatment with Prolanta has the potential to improve all of the current breast cancer therapies and may also have efficacy in triple negative breast tumors (estrogen and progesterone receptor and HER2/neu negative), the clinical development path for Prolanta has many options. Oncolix will be determining the best strategy while preclinical safety studies are ongoing; these studies are expected to be completed by the end of Q2 2010.

Monotherapy 

Combination Therapy